These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26279503)

  • 1. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.
    Whittle JR; Lickliter JD; Gan HK; Scott AM; Simes J; Solomon BJ; MacDiarmid JA; Brahmbhatt H; Rosenthal MA
    J Clin Neurosci; 2015 Dec; 22(12):1889-94. PubMed ID: 26279503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.
    MacDiarmid JA; Langova V; Bailey D; Pattison ST; Pattison SL; Christensen N; Armstrong LR; Brahmbhatt VN; Smolarczyk K; Harrison MT; Costa M; Mugridge NB; Sedliarou I; Grimes NA; Kiss DL; Stillman B; Hann CL; Gallia GL; Graham RM; Brahmbhatt H
    PLoS One; 2016; 11(4):e0151832. PubMed ID: 27050167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
    Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
    Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
    Vanhoefer U; Tewes M; Rojo F; Dirsch O; Schleucher N; Rosen O; Tillner J; Kovar A; Braun AH; Trarbach T; Seeber S; Harstrick A; Baselga J
    J Clin Oncol; 2004 Jan; 22(1):175-84. PubMed ID: 14701780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
    Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
    Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells.
    Solomon BJ; Desai J; Rosenthal M; McArthur GA; Pattison ST; Pattison SL; MacDiarmid J; Brahmbhatt H; Scott AM
    PLoS One; 2015; 10(12):e0144559. PubMed ID: 26659127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.
    Combs SE; Heeger S; Haselmann R; Edler L; Debus J; Schulz-Ertner D
    BMC Cancer; 2006 May; 6():133. PubMed ID: 16709245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
    Li L; Quang TS; Gracely EJ; Kim JH; Emrich JG; Yaeger TE; Jenrette JM; Cohen SC; Black P; Brady LW
    J Neurosurg; 2010 Aug; 113(2):192-8. PubMed ID: 20345222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme.
    White E; Bienemann A; Taylor H; Hopkins K; Cameron A; Gill S
    Contemp Clin Trials; 2012 Mar; 33(2):320-31. PubMed ID: 22101221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.
    Westphal M; Maire CL; Lamszus K
    CNS Drugs; 2017 Sep; 31(9):723-735. PubMed ID: 28791656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme.
    Patchell RA; Regine WF; Ashton P; Tibbs PA; Wilson D; Shappley D; Young B
    J Neurooncol; 2002 Oct; 60(1):37-42. PubMed ID: 12416544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
    Reardon DA; Conrad CA; Cloughesy T; Prados MD; Friedman HS; Aldape KD; Mischel P; Xia J; DiLea C; Huang J; Mietlowski W; Dugan M; Chen W; Yung WK
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1507-18. PubMed ID: 22392572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
    DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
    Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification.
    Choi SW; Jung HA; Cho HJ; Kim TM; Park CK; Nam DH; Lee SH
    Cancer Med; 2023 Aug; 12(15):15788-15796. PubMed ID: 37537946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
    Chen Y; Li R; Pan M; Shi Z; Yan W; Liu N; You Y; Zhang J; Wang X
    J Neurooncol; 2017 Jul; 133(3):477-485. PubMed ID: 28501897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
    Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
    Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
    Schäfer N; Gielen GH; Kebir S; Wieland A; Till A; Mack F; Schaub C; Tzaridis T; Reinartz R; Niessen M; Fimmers R; Simon M; Coch C; Fuhrmann C; Herrlinger U; Scheffler B; Glas M
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1581-9. PubMed ID: 27100354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.